C227: FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data

Zodro, E.; Jaroszewski, Marcin; Ida, Akinori; Wrzesińki, T.; Kwias, Zbigniew; Bluyssen, Hans A.R.; Wesoły, Joanna

doi:10.1016/s1569-9056(14)61591-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prolyl hydroxylase 3 gene, EGLN3 (PHD3), encodes a hydroxylase whose expression is HIF1α dependent [46]. Screening studies and our data have shown a differential expression of this gene in ccRCC [47,48]. According to our results, a decreased level of the EGLN3 gene expression is associated with an increased risk of metastasis.…”

Section: Discussionsupporting

confidence: 58%

The Genes—Candidates for Prognostic Markers of Metastasis by Expression Level in Clear Cell Renal Cell Cancer

et al. 2020

View full text Add to dashboard Cite

The molecular prognostic markers of metastasis are important for personalized approaches to clear cell renal cell carcinoma (ccRCC) treatment but markers for practical use are still missing. To address this gap we studied the expression of ten genes—CA9, NDUFA4L2, VWF, IGFBP3, BHLHE41, EGLN3, SAA1, CSF1R, C1QA, and FN1—through RT-PCR, in 56 ccRCC patients without metastases and with metastases. All of these, excluding CSF1R, showed differential and increased (besides SAA1) expression in non-metastasis tumors. The gene expression levels in metastasis tumors were decreased, besides CSF1R, FN1 (not changed), and SAA1 (increased). There were significant associations of the differentially expressed genes with ccRCC metastasis by ROC analysis and the Fisher exact test. The association of the NDUFA4L2, VWF, EGLN3, SAA1, and C1QA expression with ccRCC metastasis is shown for the first time. The CA9, NDUFA4L2, BHLHE4, and EGLN3 were distinguished as the strongest candidates for ccRCC metastasis biomarkers. We used an approach that presupposed that the metastasis marker was the expression levels of any three genes from the selected panel and received sensitivity (88%) and specificity (73%) levels with a relative risk of RR > 3. In conclusion, a panel of selected genes—the candidates in biomarkers of ccRCC metastasis—was created for the first time. The results might shed some light on the ccRCC metastasis processes.

show abstract

Section: Discussionsupporting

confidence: 58%